No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
QURE240621C5000
- 0.30
- -0.35-53.85%
15min DelayClose Jun 14 16:00 ET
0.35High0.30Low
0.35Open0.65Pre Close120 Volume8.55K Open Interest5.00Strike Price4.10KTurnover88.74%IV8.38%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.4477Delta0.7119Gamma27.94Leverage Ratio-0.0195Theta0.0003Rho12.51Eff Leverage0.0025Vega
Intraday
- 5D
- 1D
News
UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment
uniQure (QURE) shares rose 8% in recent Monday trading after the company obtained the regenerative medicine advanced therapy designation from the US Food and Drug Administration for AMT-130 to treat H
UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving
UniQure N.V. (NASDAQ:QURE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for uniQure N.V. (NASDAQ:QURE) shareholders, because the company has just released its latest quarterly results, and the shares gained 4.5% to US$4.89. Revenues of US$8.5m
Stifel Nicolaus Sticks to Its Buy Rating for UniQure (QURE)
UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target
Comments
$uniQure NV(QURE.US$
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
uniQure has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AMT-130, for Huntington’s disease. This designation is based on 24-month interim data from Phase I/II clinical trials released in December 2023 and represents a significant milestone.
AMT-130 is the firs...
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
uniQure has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AMT-130, for Huntington’s disease. This designation is based on 24-month interim data from Phase I/II clinical trials released in December 2023 and represents a significant milestone.
AMT-130 is the firs...
1
Analysts hold a pessimistic view for uniQure due to its weaker revenue and earnings forecast. The broad range in price targets indicates analysts anticipate varied outcomes for the company. Despite lower revenue estimates, forecasts still suggest the business will outpace the broader industry.
Read more